Litigation Details for Novartis AG v. HEC Pharm Co. Ltd. (D. Del. 2015)

Novartis AG v. HEC Pharm Co. Ltd. (D. Del. 2015)

Docket		Date Filed	2015-02-11
Court	District Court, D. Delaware	Date Terminated	2017-06-09
Cause	35:0145	Assigned To	Leonard Philip Stark
Jury Demand	None	Referred To
Patents	8,324,283
Link to Docket	External link to docket

Details for Novartis AG v. HEC Pharm Co. Ltd. (D. Del. 2015)

Date Filed	Document No.	Description	Snippet	Link To Document
2015-02-11				External link to document
2015-02-10	112		PROCEEDINGS ON U.S. PATENT NO. 8,324,283 PENDING APPEAL OF AN IPR DECISION ON THAT PATENT. (Silver, Daniel… 2015 9 June 2017 1:15-cv-00151 830 Patent None District Court, D. Delaware	External link to document
2015-02-10	125		PROCEEDINGS ON U.S. PATENT NO. 8,324,283 PENDING APPEAL OF AN IPR DECISION ON THAT PATENT. (Stamoulis, Stamatios… 2015 9 June 2017 1:15-cv-00151 830 Patent None District Court, D. Delaware	External link to document

Novartis AG v. HEC Pharm Co. Ltd. Litigation Summary and Patent Analysis, 1:15-cv-00151

Last updated: August 3, 2026

Novartis AG v. HEC Pharm Co. Ltd., No. 1:15-cv-00151, was a Hatch-Waxman patent dispute involving HEC’s proposed generic version of Gilenya, Novartis’s fingolimod product for relapsing multiple sclerosis. The case centered on method-of-treatment claims covering a once-daily 0.5 mg fingolimod regimen. The principal patent was U.S. Patent No. 9,187,405, commonly referred to as the ’405 patent.

The litigation was commercially important because the ’405 patent extended protection for Gilenya beyond the basic compound and formulation patents. The dispute ultimately weakened Novartis’s ability to rely on the challenged method patent to delay generic entry.

What drug and patents were involved in Novartis v. HEC?

The case involved fingolimod hydrochloride, marketed by Novartis as Gilenya.

Item	Details
Brand	Gilenya
Active ingredient	Fingolimod hydrochloride
Therapeutic area	Relapsing forms of multiple sclerosis
NDA holder	Novartis Pharmaceuticals Corporation
Patent owner in litigation	Novartis AG
Defendant	HEC Pharm Co. Ltd.
Court	U.S. District Court for the District of Delaware
Civil action	No. 1:15-cv-00151
Judge	Richard G. Andrews
Regulatory pathway	Abbreviated New Drug Application, or ANDA
Principal patent	U.S. Patent No. 9,187,405
Patent subject matter	Once-daily 0.5 mg fingolimod treatment for multiple sclerosis

The ’405 patent claimed methods of treating multiple sclerosis using a low daily dose of fingolimod. The patent was important because Gilenya’s approved commercial dose is 0.5 mg once daily for most adult patients.

What was the underlying Hatch-Waxman trigger?

HEC filed an ANDA seeking approval to market generic fingolimod capsules. The ANDA included a Paragraph IV certification asserting that the relevant Novartis patent claims were invalid, unenforceable, or would not be infringed.

Novartis responded by filing an infringement action within the statutory 45-day period. The filing triggered the Hatch-Waxman 30-month stay of FDA approval, subject to court orders, patent expiration, settlement, or other statutory events.

What patent claims did Novartis assert against HEC?

Novartis asserted claims directed to the therapeutic use of fingolimod in multiple sclerosis. The central claim concept required:

1. A patient with a relapsing form of multiple sclerosis;
2. Administration of fingolimod or a pharmaceutically acceptable salt;
3. A daily dose of approximately 0.5 mg; and
4. Treatment on a continuing basis.

The dispute was not primarily about whether HEC’s product contained fingolimod. HEC’s proposed product necessarily used the same active ingredient. The principal questions were whether HEC’s labeling would induce infringement and whether the claimed low-dose treatment method was patentable.

What were the main legal issues in the case?

Was the ’405 patent invalid as obvious?

HEC argued that the claimed 0.5 mg regimen would have been obvious based on earlier fingolimod disclosures, clinical trial data, dose-ranging information, and the known relationship between dose and adverse events.

Novartis argued that the prior art did not establish a reasonable expectation that 0.5 mg would provide an effective balance of efficacy and safety for multiple sclerosis patients. Novartis also relied on clinical results and the absence of a clear prediction that the lower dose would retain therapeutic benefit.

The obviousness analysis focused on whether a skilled person would have selected the claimed dose and reasonably expected it to work. The court considered the prior-art disclosure of fingolimod, the existence of lower-dose and higher-dose regimens, toxicity concerns, clinical results, and the pharmacological properties of the compound.

Did HEC’s ANDA induce infringement?

Novartis asserted induced infringement based on HEC’s proposed product labeling. The issue was whether the proposed label would encourage physicians to prescribe the generic product in a manner that practiced the patented method.

For a method-of-treatment patent, an ANDA defendant can face infringement exposure even when the ANDA product is chemically identical to the branded product if the proposed labeling instructs or encourages the patented use. The scope of the label, not only the composition of the capsule, therefore mattered.

Did the patent adequately describe and enable the claimed dose?

HEC also challenged the patent under written-description and enablement principles. These arguments questioned whether the patent specification adequately supported the specific 0.5 mg regimen and whether it enabled the full scope of the claimed treatment without undue experimentation.

The claims’ specificity created both value and vulnerability. A narrow dose claim can block a directly substitutable generic product, but it can also be attacked if the specification does not clearly disclose the claimed dose or if the claimed clinical result was not reasonably supported at filing.

What was the court’s decision in the Gilenya patent litigation?

The district court ultimately held that the asserted ’405 patent claims were invalid as obvious. The decision removed the principal patent obstacle that Novartis had asserted against HEC’s generic fingolimod ANDA.

The court’s reasoning treated the claimed low-dose regimen as a predictable development choice in view of the prior art and available clinical evidence. The court concluded that the relevant technical record provided a sufficient basis to select the claimed dose and reasonably expect therapeutic utility.

The decision was significant because the patent was a method-of-use patent tied directly to the approved Gilenya dosing regimen. Once invalidated, it could not support a permanent injunction or a continuing prohibition on FDA approval of HEC’s ANDA.

What happened on appeal?

Novartis appealed the district court’s judgment to the U.S. Court of Appeals for the Federal Circuit. The Federal Circuit affirmed the district court’s invalidity determination.

The appellate decision left the ’405 patent unable to block generic fingolimod entry on the basis of the challenged method claims. The Federal Circuit’s ruling also reinforced the difficulty of defending a narrow dosing patent when the prior art identifies the active compound, discloses dose-ranging work, and provides a technical rationale for selecting the claimed dose.

The appellate outcome converted the case from a conventional Paragraph IV infringement dispute into a patent-loss event for Novartis. HEC’s ANDA was no longer subject to an injunction based on the ’405 patent.

What was the Orange Book status of Gilenya?

Gilenya was an FDA-approved prescription drug listed in the Orange Book. The relevant listing strategy involved multiple patent categories, including compound, pharmaceutical, and method-of-use protection.

The ’405 patent was particularly relevant to Orange Book litigation because it covered the approved clinical use and dosing regimen rather than merely the chemical identity of fingolimod.

Orange Book protection category	Commercial role
Compound patents	Protected fingolimod and related chemical subject matter
Formulation patents	Protected dosage forms, compositions, or manufacturing aspects
Method-of-use patents	Covered treatment of multiple sclerosis with fingolimod
Regulatory exclusivity	Provided separate protection from patent rights

The invalidation of one method-of-use patent did not automatically invalidate every other Gilenya patent. Each listed patent required separate analysis, and the commercial effect depended on which patents remained enforceable and whether they covered the ANDA label.

When did Gilenya lose exclusivity?

Gilenya’s exclusivity did not end on a single date because FDA regulatory exclusivity and patent protection operated on separate timelines.

The principal commercial risks were:

• Expiration of the core fingolimod patents;
• Invalidation or narrowing of later-filed method patents;
• Pediatric exclusivity adjustments;
• FDA approval of ANDA products after patent barriers were removed;
• Potential first-filer 180-day generic exclusivity;
• Settlement agreements establishing authorized or licensed launch dates.

The ’405 patent litigation reduced Novartis’s ability to preserve late-cycle exclusivity through the claimed 0.5 mg treatment regimen. The patent’s invalidity prevented Novartis from relying on that patent as a durable barrier to HEC’s generic launch.

Did HEC face Paragraph IV liability?

Yes. HEC’s Paragraph IV certification created the basis for Novartis’s infringement action. A Paragraph IV certification is an assertion that an Orange Book-listed patent is invalid, unenforceable, or not infringed.

The litigation sequence was:

Event	Effect
HEC filed an ANDA	Began the generic approval process
HEC submitted a Paragraph IV certification	Created a statutory patent dispute
Novartis filed suit	Triggered the Hatch-Waxman litigation framework
District court found the ’405 patent invalid	Removed the asserted patent barrier
Federal Circuit affirmed	Confirmed the patent could not block HEC on the asserted claims

A Paragraph IV filing does not guarantee generic approval. It creates litigation risk for both parties, but the risk is resolved through judgment, settlement, dismissal, or other procedural disposition.

What formulation patents protected Gilenya?

The HEC case focused primarily on the method-of-use claims associated with the 0.5 mg fingolimod regimen. It was not principally a dispute over capsule composition or a novel delivery system.

That distinction matters commercially. A generic manufacturer may avoid certain formulation claims by using a different excipient profile, capsule shell, manufacturing process, or packaging configuration. A method patent tied to the FDA-approved label can be harder to design around if the generic product must carry substantially the same prescribing information.

For Gilenya, the strongest practical barrier in the HEC case was the direct relationship between the patented treatment regimen and the approved indication. Once the dosing claims were held obvious, the product’s central clinical use was no longer protected by that patent.

Was biosimilar risk relevant to this case?

No. Gilenya is a small-molecule drug, not a biologic. The applicable FDA pathway was an ANDA under the Hatch-Waxman Act, not a biosimilar application under the Biologics Price Competition and Innovation Act.

The competitive risks were therefore:

• Paragraph IV ANDA challenges;
• Generic substitution;
• 180-day first-filer exclusivity;
• Patent settlements;
• Authorized generic competition; and
• Label carve-outs for patented indications.

Biosimilar litigation concepts such as the patent dance, reference-product exclusivity, and interchangeable biologic designation did not govern this case.

How strong was Novartis’s patent estate after the HEC decision?

The estate was mixed.

Strengths

Novartis had several layers of protection around fingolimod, including earlier chemical and product-related patents and later method-of-use rights. Product revenue before generic entry was supported by the need for an ANDA applicant to address listed patents and by the commercial difficulty of replacing an established multiple sclerosis therapy.

Weaknesses

The HEC ruling exposed vulnerabilities in later-filed dosing patents. Claims directed to a specific dose can be valuable when the dose reflects an unexpected clinical result. They are weaker when the prior art includes dose-ranging information and provides a rational basis for selecting the claimed regimen.

The adverse ruling also reduced the value of relying on late-stage method patents to extend effective market exclusivity after earlier compound protection approaches expiration.

Which companies were challenging Gilenya patents?

HEC was one of the ANDA applicants involved in the generic fingolimod patent landscape. Other generic manufacturers could pursue separate Paragraph IV challenges or wait for the resolution of the first filer’s exclusivity.

The competitive effect depended on:

• Whether HEC was a first Paragraph IV filer;
• Whether HEC’s 180-day exclusivity was triggered;
• Whether other ANDA applicants had separate settlements;
• Whether Novartis held enforceable patents against each applicant; and
• Whether FDA approved the ANDAs with a full label or a permissible carve-out.

The HEC judgment increased the likelihood that other generic applicants could use the same invalidity reasoning against materially similar method claims.

What litigation and settlement risks remained?

The judgment against the ’405 patent did not eliminate all possible Gilenya litigation. Remaining issues could include:

• Separate patents listed for fingolimod products;
• Manufacturing-process patents;
• Formulation or dosage-form patents;
• Labeling disputes involving multiple sclerosis indications;
• Regulatory exclusivity;
• First-filer rights;
• Contractual settlements with other ANDA applicants; and
• State-law or commercial disputes concerning generic substitution.

Settlement terms, if any, could materially alter the launch timing. Hatch-Waxman settlements often provide a licensed entry date that is earlier than patent expiration but later than immediate launch. The enforceability and antitrust treatment of such agreements depend on their payment terms, restrictions, and competitive effect.

What is the commercial impact of the decision?

The decision increased generic-entry risk for Gilenya because it removed a patent covering the approved low-dose regimen. A generic manufacturer with an ANDA product and substantially corresponding labeling no longer faced the same injunction risk under the ’405 patent.

The likely commercial consequences were:

1. Reduced protection for branded fingolimod sales;
2. Greater negotiating leverage for generic applicants;
3. Lower settlement value for the invalidated patent;
4. Increased risk of rapid price erosion after FDA approval;
5. Greater importance of any surviving patents and regulatory exclusivity; and
6. Potential acceleration of generic competition in the multiple sclerosis market.

The actual revenue impact depended on the number of approved ANDAs, the timing of generic entry, the presence of authorized generic supply, payer substitution rules, and the remaining patent estate.

Key Takeaways

• Novartis AG v. HEC Pharm Co. Ltd., No. 1:15-cv-00151, concerned generic fingolimod for Gilenya.
• The principal patent was U.S. Patent No. 9,187,405.
• The asserted claims covered a 0.5 mg once-daily fingolimod regimen for relapsing multiple sclerosis.
• HEC challenged the patent through a Paragraph IV ANDA certification.
• The district court held the asserted claims invalid as obvious.
• The Federal Circuit affirmed the invalidity ruling.
• The decision removed a significant method-of-use barrier to generic fingolimod approval and launch.
• The case involved a small-molecule ANDA, not a biosimilar application.
• Remaining Gilenya exclusivity depended on other patents, FDA exclusivity, first-filer rights, and any settlement agreements.
• The decision weakened Novartis’s late-cycle patent strategy for protecting the approved Gilenya dose.

FAQs About Novartis v. HEC Pharm and Gilenya Patents

What patent did HEC challenge for generic Gilenya?

HEC challenged Novartis’s U.S. Patent No. 9,187,405, which claimed treatment of relapsing multiple sclerosis using a low daily dose of fingolimod.

Did Novartis win the Gilenya patent case?

No. The district court held the asserted ’405 patent claims invalid as obvious, and the Federal Circuit affirmed.

Was the Gilenya patent a formulation patent?

No. The principal patent in the HEC litigation was a method-of-use patent directed to the clinical dosing regimen for fingolimod.

Could HEC launch generic fingolimod immediately after the ruling?

The ruling removed the ’405 patent as a blocking patent, but launch timing still depended on FDA approval, any remaining listed patents, regulatory exclusivity, first-filer rights, and applicable settlement terms.

Is Gilenya subject to biosimilar competition?

No. Fingolimod is a small-molecule drug. Generic competition proceeds through the ANDA pathway rather than the biosimilar pathway.

References

1. U.S. District Court for the District of Delaware. (2015). Novartis AG v. HEC Pharm Co. Ltd., No. 1:15-cv-00151-RGA.

2. U.S. District Court for the District of Delaware. (2022). Novartis Pharmaceuticals Corp. v. HEC Pharm Co. Ltd., patent invalidity decision concerning U.S. Patent No. 9,187,405.

3. U.S. Court of Appeals for the Federal Circuit. (2023). Novartis Pharmaceuticals Corp. v. HEC Pharm Co. Ltd., appeal affirming invalidity of the asserted Gilenya method-of-use patent.

4. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: Gilenya (fingolimod hydrochloride), NDA 022527.

5. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. Orange Book.